article thumbnail

How the FDA’s new nutrition labels could prod the food industry to get healthier 

STAT

A new government proposal to display nutritional labels on the front of food packaging is aimed at helping Americans make more informed choices about what they eat. An eventual side effect, research and expert commentary suggests, could be nudging the food industry to make healthier food, too.

Labelling 328
article thumbnail

Weight loss drugs without a prescription? Study warns it’s a ‘very risky business’

STAT

In the face of ongoing shortages of the obesity and diabetes medications known as GLP-1s, patients have resorted to a wide array of sources for the drugs, including medical spas and telehealth sites that prescribe compounded versions of the drugs. One sample also contained signs of potential bacterial contamination during manufacturing.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Pharmalittle: Lilly diabetes drug back on shelves after two-month shortage; AbbVie sued for human rights violations over Humira pricing

STAT

… Eli Lilly says that all doses of its new Mounjaro diabetes drug are now available after social-media enthusiasm about weight-loss benefits sparked a two-month-long shortage , Bloomberg News tells us. last May to help people with type 2 diabetes control their blood sugar levels. The drug was approved in the U.S.

Diabetes 243
article thumbnail

Novo Nordisk’s Ozempic gains USFDA approves to cut risk of diabetic kidney disease progression

Express Pharma

The US FDA has approved Novo Nordisk’s Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease (CKD), the Danish drugmaker said on Tuesday.

article thumbnail

STAT+: Pharmalittle: We’re reading about fake Ozempic, the FTC policing pharma, and more

STAT

last year after taking suspected fake versions of Novo Nordisk’s diabetes drug Ozempic , Reuters reports, citing data from America’s Poison Centers. One Ozempic and similar diabetes medicines have been increasingly used off label for weight loss. Food and Drug Administration to identify public health risks.

Labelling 254
article thumbnail

STAT+: With weight loss drug ads, telehealth companies wade into a regulatory gray area

STAT

Novo Nordisk’s drug Wegovy is FDA-approved for weight loss in adults, while the company’s drug Ozempic is approved to treat diabetes but is also prescribed off-label for weight loss. 

Labelling 256
article thumbnail

STAT+: Pharmalittle: FDA finds ‘potential systemic bias’ in Amgen cancer drug trial; drugmakers organize to push back on antitrust reviews

STAT

The head of Eli Lilly’s burgeoning diabetes and obesity franchise is retiring at the end of the year, The Wall Street Journal notes. Mike Mason, executive vice president and president of Lilly Diabetes & Obesity, is leaving after 34 years with the drugmaker. Continue to STAT+ to read the full story…

Diabetes 260